Zebra Technologies Corp. Cl A Stock Rises Wednesday, Outperforms Market

Neoleukin Therapeutics Inc

Change company Symbol lookup

Select an option...

NLTX Neoleukin Therapeutics Inc

CTO CTO Realty Growth Inc

WHR Whirlpool Corp

OTIS Otis Worldwide Corp

GME GameStop Corp

ECF Ellsworth Growth and Income Fund Ltd

SILK Silk Road Medical Inc

HLVX Hillevax Inc

AIZ Assurant Inc

NOTV Inotiv Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value

Company profile

Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.

Zebra Technologies Corp. Cl A Stock Rises Wednesday, Outperforms Market

5:34 pm ET November 23, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Zebra Technologies Corp. Cl A (ZBRA) rose 3.68% to $270.66 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.59% to 4,027.26 and the Dow Jones Industrial Average rising 0.28% to 34,194.06. This was the stock's fourth consecutive day of gains. Zebra Technologies Corp. Cl A closed $344.34 short of its 52-week high ($615.00), which the company achieved on December 10th.

The stock outperformed some of its competitors Wednesday, as Danaher Corp. (DHR) rose 0.50% to $263.35, Hitachi Ltd. ADR (6501.TO) rose 1.38% to $106.35, and HP Inc. (HPQ) rose 1.80% to $29.91. Trading volume (464,590) eclipsed its 50-day average volume of 453,439.

Data source: Dow Jones Market Data, FactSet. Data compiled November 23, 2022.

(END) Dow Jones Newswires

November 23, 2022 17:34 ET (22:34 GMT)